insulin like growth factor binding protein 7Genealiases: AGM · FSTL2 · IBP-7 · IGFBP-7 · IGFBP-7v · IGFBPRP1
Q-omics provides the consensus-scored IGFBP7 profile across patient tissues and cancer cell-line models. IGFBP7 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IGFBP7 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, IGFBP7 RNA expression shows 26,137 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where IGFBP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGFBP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGFBP7 survival associations across molecular data types. IGFBP7 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGFBP7 RNA expression–survival associations across cancer types. High IGFBP7 expression shows unfavorable associations in UVM, MESO, ACC and LGG, but favorable associations in KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IGFBP7 RNA expression.
This table summarizes IGFBP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for IGFBP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGFBP7 shows lower tumor expression in KICH, THCA, UCEC and BLCA and higher tumor expression in HNSC and COAD. The HNSC box plot shows higher IGFBP7 RNA expression in tumor versus normal tissue (log2 FC = +2.808, t-test p < 0.001).
This table shows molecular features associated with IGFBP7 in patient tissues and cancer cell lines. In patient samples, IGFBP7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGFBP7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Myeloma.
